Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000552183 | SCV000657079 | likely pathogenic | Bethlem myopathy 1A | 2022-07-19 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the triple helix domain of COL6A1. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In COL6A1, variants at these glycine residues are significantly enriched in individuals with autosomal dominant disease (PMID: 15689448, 24038877) compared to the general population (ExAC). ClinVar contains an entry for this variant (Variation ID: 476440). This variant has not been reported in the literature in individuals affected with COL6A1-related conditions. This variant is not present in population databases (gnomAD no frequency). This variant, c.846_854del, results in the deletion of 3 amino acid(s) of the COL6A1 protein (p.Glu282_Gly284del), but otherwise preserves the integrity of the reading frame. |
Eurofins Ntd Llc |
RCV000596227 | SCV000702889 | uncertain significance | not provided | 2016-12-21 | criteria provided, single submitter | clinical testing |